Long-Term Survival in Patients With Advanced Melanoma
JAMA Network Open · 14.08.2024 · 7 (8) · e2426641
DOI: 10.1001/jamanetworkopen.2024.26641 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 14.08.2024. Verfasst von Olivier J van Not und 20 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
IMPORTANCE Long-term survival data from clinical trials show that survival curves of patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) gradually reach a plateau, suggesting that patients have a chance of achieving long-term survival. OBJECTIVE To investigate long-term survival in patients with advanced melanoma treated with ICIs outside clinical trials. DESIGN, SETTING, AND PARTICIPANTS Cohort study using prospectively collected data from the nationwide Dutch Melanoma Treatment Registry, including patients in the Netherlands with advanced melanoma treated with first-line ICIs from 2012 to 2019. Data were analyzed from January to September 2023. EXPOSURES Patients were treated with first-line ipilimumab-nivolumab, antibodies that target programmed cell death (anti–PD-1), or ipilimumab. MAIN OUTCOMES AND MEASURES Progression-free survival (PFS) and melanoma-specific survival were analyzed, and a Cox proportional hazards model was used to investigate factors associated with PFS after reaching partial response (PR) or complete response (CR). RESULTS A total of 2490 patients treated with first-line ICIs were included (median [IQR] age, 65.0 [55.3-73.0] years; 1561 male patients [62.7%]). Most patients had an Eastern Cooperative Oncology Group Performance Status of 1 or lower (2202 patients [88.5%]) and normal lactate dehydrogenase levels (1715 patients [68.9%]). PFS for all patients was 23.4% (95% CI, 21.7%-25.2%) after 3 years and 19.7% (95% CI, 18.0%-21.4%) after 5 years. Overall survival for all patients was 44.0% (95% CI, 42.1%-46.1%) after 3 years and 35.9% (95% CI, 33.9%-38.0%) after 5 years. Patients with metastases in 3 or more organ sites had a significantly higher hazard of progression after reaching PR or CR (adjusted hazard ratio, 1.37; 95% CI, 1.11-1.69). CONCLUSIONS AND RELEVANCE This cohort study of patients with advanced melanoma treated with ICIs in clinical practice showed that their survival reached a plateau, comparable with patients participating in clinical trials. These findings can be used in daily clinical practice to guide long-term surveillance strategies and inform both physicians and patients regarding long-term treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Zitieren
APA
van Not, O. J., van den Eertwegh, A. J. M., Jalving, H., Bloem, M., Haanen, J. B., van Rijn, R. S., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., de Groot J W B, J. W., Hospers, G. A. P., Kapiteijn, E., Leeneman, B., D, P., Stevense-den Boer, M., van der Veldt, A. A. M., Vreugdenhil G, G., Wouters, M. W. J. M., …, & Suijkerbuijk, K. P. M. (2024). Long-Term Survival in Patients With Advanced Melanoma. JAMA Network Open, 7(8), e2426641. https://doi.org/10.1001/jamanetworkopen.2024.26641
Vancouver
van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, et al. Long-Term Survival in Patients With Advanced Melanoma. JAMA Network Open. 2024;7(8):e2426641. doi:10.1001/jamanetworkopen.2024.26641
BibTeX
@article{vanNot2024,
author = {van Not, Olivier J and van den Eertwegh, Alfons J M and Jalving, Hilde and Bloem, Manja and Haanen, John B and van Rijn, Rozemarijn S and Aarts, Maureen J B and van den Berkmortel, Franchette W P J and Blank, Christian U and Boers-Sonderen, Marye J and de Groot J W B, Jan Willem and Hospers, Geke A P and Kapiteijn, Ellen and Leeneman, Brenda and D, Piersma and Stevense-den Boer, Marion and van der Veldt, Astrid A M and Vreugdenhil G, Gerard and Wouters, Michel W J M and Blokx, Willeke A M and Suijkerbuijk, Karijn P M},
title = {Long-Term Survival in Patients With Advanced Melanoma},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {8},
pages = {e2426641},
doi = {10.1001/jamanetworkopen.2024.26641}
}
EUVIMED